Vaxcyte Inc (PCVX) - Net Assets
Based on the latest financial reports, Vaxcyte Inc (PCVX) has net assets worth $2.69 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.05 Billion) and total liabilities ($360.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Vaxcyte Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.69 Billion |
| % of Total Assets | 88.17% |
| Annual Growth Rate | 74.71% |
| 5-Year Change | 845.54% |
| 10-Year Change | N/A |
| Growth Volatility | 165.85 |
Vaxcyte Inc - Net Assets Trend (2017–2025)
This chart illustrates how Vaxcyte Inc's net assets have evolved over time, based on quarterly financial data. Also explore PCVX current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Vaxcyte Inc (2017–2025)
The table below shows the annual net assets of Vaxcyte Inc from 2017 to 2025. For live valuation and market cap data, see market cap of Vaxcyte Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.69 Billion | -18.76% |
| 2024-12-31 | $3.31 Billion | +166.50% |
| 2023-12-31 | $1.24 Billion | +30.08% |
| 2022-12-31 | $953.61 Million | +235.76% |
| 2021-12-31 | $284.02 Million | -17.88% |
| 2020-12-31 | $345.84 Million | +425.12% |
| 2019-12-31 | $-106.37 Million | -84.27% |
| 2018-12-31 | $-57.73 Million | -286.59% |
| 2017-12-31 | $30.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vaxcyte Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 212535900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $134.00K | 0.00% |
| Other Comprehensive Income | $1.59 Million | 0.06% |
| Other Components | $4.84 Billion | 180.18% |
| Total Equity | $2.69 Billion | 100.00% |
Vaxcyte Inc Competitors by Market Cap
The table below lists competitors of Vaxcyte Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KakaoBank Corp
KO:323410
|
$7.64 Billion |
|
LandMark Optoelectronics
TWO:3081
|
$7.64 Billion |
|
TongKun Group Co Ltd
SHG:601233
|
$7.65 Billion |
|
Commerce Bancshares Inc
NASDAQ:CBSH
|
$7.65 Billion |
|
Sangfor Technologies Inc Class A
SHE:300454
|
$7.63 Billion |
|
Inpost SA
AS:INPST
|
$7.62 Billion |
|
China Merchants Port Group Co Ltd
SHE:001872
|
$7.62 Billion |
|
Thai Beverage Public Company Limited
F:T6W
|
$7.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaxcyte Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,305,819,000 to 2,685,510,000, a change of -620,309,000 (-18.8%).
- Net loss of 766,628,000 reduced equity.
- Other comprehensive income increased equity by 5,460,000.
- Other factors increased equity by 140,859,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-766.63 Million | -28.55% |
| Other Comprehensive Income | $5.46 Million | +0.2% |
| Other Changes | $140.86 Million | +5.25% |
| Total Change | $- | -18.76% |
Book Value vs Market Value Analysis
This analysis compares Vaxcyte Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.11x to 2.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $8.68 | $53.01 | x |
| 2018-12-31 | $-2.26 | $53.01 | x |
| 2019-12-31 | $-2.18 | $53.01 | x |
| 2020-12-31 | $11.71 | $53.01 | x |
| 2021-12-31 | $5.47 | $53.01 | x |
| 2022-12-31 | $14.70 | $53.01 | x |
| 2023-12-31 | $12.77 | $53.01 | x |
| 2024-12-31 | $27.10 | $53.01 | x |
| 2025-12-31 | $19.73 | $53.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaxcyte Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-28.55%) is below the historical average (-23.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -55.72% | 0.00% | 0.00x | 1.28x | $-20.33 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.71 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.64 Million |
| 2020 | -25.80% | 0.00% | 0.00x | 1.14x | $-123.80 Million |
| 2021 | -35.24% | 0.00% | 0.00x | 1.14x | $-128.48 Million |
| 2022 | -23.44% | 0.00% | 0.00x | 1.06x | $-318.85 Million |
| 2023 | -32.43% | 0.00% | 0.00x | 1.13x | $-526.31 Million |
| 2024 | -14.03% | 0.00% | 0.00x | 1.06x | $-794.51 Million |
| 2025 | -28.55% | 0.00% | 0.00x | 1.13x | $-1.04 Billion |
Industry Comparison
This section compares Vaxcyte Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $103,396,513
- Average return on equity (ROE) among peers: -329.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaxcyte Inc (PCVX) | $2.69 Billion | -55.72% | 0.13x | $7.63 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.45 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $184.86 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $-2.99 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $627.01 Million | -44.91% | 0.25x | $3.82 Billion |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more